Compare American Tower Corp (AMT) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Tower Corp vs Cassava Sciences Inc — how do they compare? American Tower Corp trades at $172 (market cap $79.00B), while Cassava Sciences Inc trades at $0.95 (market cap $47.75M). The key difference: American Tower Corp is far larger — about 1654.5× Cassava Sciences Inc's market cap, and American Tower Corp pays a 4.12% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| AMT | FLNA | |
|---|---|---|
Market Cap | $79.00B | $47.75M |
Sector | Real Estate | Health |
52-Week High | $211.88 | $4.64 |
52-Week Low | $162.11 | $0.87 |
Enterprise Value | $122.53B | -$34.93M |
Dividend Yield | 4.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Tower (AMT) trades at $169.11, down 1.99% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.86 exceeding the $1.57 estimate. Revenue trends show steady growth from $10.1B in 2024 to $10.6B in 2025, with net income margins improving to 23.76%. Recent news highlights strong Q2 2026 results and institutional buying activity.
Wall Street maintains strong bullish sentiment with 39 buy ratings and a $206.17 price target representing 22% upside potential. Key risks include interest rate sensitivity and DISH Network churn impacts. The stock offers defensive characteristics with resilient telecom demand and 5G/6G growth catalysts, though high debt levels and bearish technical signals warrant caution near-term.
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
